Dupont Capital Management Corp increased its position in Chemed Co. (NYSE:CHE) by 40.0% during the third quarter, HoldingsChannel.com reports. The fund owned 5,770 shares of the company’s stock after acquiring an additional 1,649 shares during the quarter. Dupont Capital Management Corp’s holdings in Chemed were worth $1,844,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Fort L.P. acquired a new stake in Chemed during the 2nd quarter valued at $120,000. Cerebellum GP LLC acquired a new stake in Chemed during the 3rd quarter valued at $148,000. Tower Research Capital LLC TRC grew its holdings in Chemed by 70.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 544 shares of the company’s stock valued at $175,000 after buying an additional 224 shares during the last quarter. We Are One Seven LLC acquired a new stake in Chemed during the 3rd quarter valued at $228,000. Finally, Hollencrest Capital Management acquired a new stake in Chemed during the 3rd quarter valued at $231,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

In other news, Director Donald E. Saunders sold 300 shares of the firm’s stock in a transaction on Monday, August 20th. The stock was sold at an average price of $319.22, for a total transaction of $95,766.00. Following the sale, the director now owns 8,701 shares in the company, valued at $2,777,533.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kevin J. Mcnamara sold 7,000 shares of the firm’s stock in a transaction on Friday, November 2nd. The stock was sold at an average price of $305.98, for a total value of $2,141,860.00. Following the sale, the insider now owns 141,293 shares in the company, valued at approximately $43,232,832.14. The disclosure for this sale can be found here. Insiders have sold 19,633 shares of company stock worth $6,163,462 in the last 90 days. Insiders own 4.90% of the company’s stock.

CHE stock opened at $310.56 on Friday. Chemed Co. has a 52-week low of $227.98 and a 52-week high of $335.99. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.11 and a current ratio of 1.14. The firm has a market cap of $4.92 billion, a PE ratio of 57.94, a price-to-earnings-growth ratio of 2.69 and a beta of 1.23.

Chemed (NYSE:CHE) last posted its quarterly earnings data on Monday, October 29th. The company reported $3.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.80 by $0.27. Chemed had a return on equity of 35.13% and a net margin of 11.73%. The business had revenue of $444.15 million for the quarter, compared to analysts’ expectations of $445.16 million. During the same quarter last year, the firm earned $2.15 earnings per share. The business’s revenue was up 6.4% on a year-over-year basis. As a group, equities research analysts predict that Chemed Co. will post 11.41 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Monday, November 12th will be issued a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 0.39%. The ex-dividend date of this dividend is Thursday, November 8th. Chemed’s dividend payout ratio (DPR) is 22.39%.

A number of equities research analysts have commented on the company. Zacks Investment Research reiterated a “buy” rating and set a $342.00 target price on shares of Chemed in a report on Monday. Bank of America assumed coverage on Chemed in a report on Friday, October 12th. They set a “buy” rating and a $390.00 target price on the stock. ValuEngine cut Chemed from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 2nd. Finally, Royal Bank of Canada increased their target price on Chemed to $321.00 and gave the company a “market perform” rating in a report on Monday, July 30th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $332.00.

COPYRIGHT VIOLATION WARNING: “Dupont Capital Management Corp Grows Position in Chemed Co. (CHE)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2018/11/16/dupont-capital-management-corp-grows-position-in-chemed-co-che.html.

Chemed Profile

Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.

Further Reading: Discount Rate

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.